Skip to content

Study · Systematic review · n = 6,213 · 2023

6 results

Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis.

Chen H, Li XZ, Chen JQ, Ren TS, Zhang YS, Wang YN, Zhao QC

Medicine1 Jul 2023Cited by 11 (Europe PMC)

PMID37417602 (opens in a new tab)PMCIDPMC10328610 (opens in a new tab)DOI10.1097/md.0000000000034122 (opens in a new tab)PepBankPUB-37417602
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, semaglutide 2.0 mg ranked first for HbA1c lowering among the GLP-1 receptor agonist regimens in the network meta-analysis.

    In plain wordsIn adults with type 2 diabetes, semaglutide 2.0 mg lowered HbA1c the most among the GLP-1 drug regimens compared.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c lowering, rank among regimens
    Study

    n = 6,213

    Comparator
    Other GLP-1RA regimens
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.0 mgAs given in this study (human).

    Source sentences

    Summary
    A pairwise comparison of glycosylated hemoglobin type A1C (HbA1c) lowering effects showed that once-weekly GLP-1 receptor agonists were significantly better than placebo, and their glucose-lowering intensity was Semaglutide 2.0mg, Semaglutide 1.0mg, Dulaglutide 4.5mg, and Semaglutide 0.5mg, Dulaglut…
    1 context sentence
    Summary · context
    Randomized clinical trials (RCTs) enrolling participants with diabetes mellitus type 2 and a follow-up of at least 12 weeks were included, for which 4 eligible GLP-1RAs Exenatide, Dulaglutide, Semaglutide, Loxenatide were compared with either each other or placebo.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, semaglutide 1.0 mg ranked second for HbA1c lowering, after semaglutide 2.0 mg, in the network meta-analysis.

    In plain wordsIn adults with type 2 diabetes, semaglutide 1.0 mg lowered HbA1c second most among the GLP-1 drug regimens compared.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c lowering, rank among regimens
    Study

    n = 6,213

    Comparator
    Other GLP-1RA regimens
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.0 mgAs given in this study (human).

    Source sentences

    Summary
    A pairwise comparison of glycosylated hemoglobin type A1C (HbA1c) lowering effects showed that once-weekly GLP-1 receptor agonists were significantly better than placebo, and their glucose-lowering intensity was Semaglutide 2.0mg, Semaglutide 1.0mg, Dulaglutide 4.5mg, and Semaglutide 0.5mg, Dulaglut…
    1 context sentence
    Summary · context
    Randomized clinical trials (RCTs) enrolling participants with diabetes mellitus type 2 and a follow-up of at least 12 weeks were included, for which 4 eligible GLP-1RAs Exenatide, Dulaglutide, Semaglutide, Loxenatide were compared with either each other or placebo.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, semaglutide 0.5 mg was listed after semaglutide 2.0 mg, semaglutide 1.0 mg and dulaglutide 4.5 mg for HbA1c lowering.

    In plain wordsIn adults with type 2 diabetes, semaglutide 0.5 mg lowered HbA1c less than higher semaglutide doses and dulaglutide 4.5 mg.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c lowering, rank among regimens
    Study

    n = 6,213

    Comparator
    Other GLP-1RA regimens
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.5 mgAs given in this study (human).

    Source sentences

    Summary
    A pairwise comparison of glycosylated hemoglobin type A1C (HbA1c) lowering effects showed that once-weekly GLP-1 receptor agonists were significantly better than placebo, and their glucose-lowering intensity was Semaglutide 2.0mg, Semaglutide 1.0mg, Dulaglutide 4.5mg, and Semaglutide 0.5mg, Dulaglut…
    1 context sentence
    Summary · context
    Randomized clinical trials (RCTs) enrolling participants with diabetes mellitus type 2 and a follow-up of at least 12 weeks were included, for which 4 eligible GLP-1RAs Exenatide, Dulaglutide, Semaglutide, Loxenatide were compared with either each other or placebo.

Studies that did not test the peptide alone3

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, pooled once-weekly GLP-1 receptor agonists (including semaglutide) lowered HbA1c significantly more than placebo.

    In plain wordsIn adults with type 2 diabetes, once-weekly GLP-1 drugs as a group, semaglutide included, lowered HbA1c more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c lowering, once-weekly GLP-1RAs pooled
    Study

    n = 6,213

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    A pairwise comparison of glycosylated hemoglobin type A1C (HbA1c) lowering effects showed that once-weekly GLP-1 receptor agonists were significantly better than placebo, and their glucose-lowering intensity was Semaglutide 2.0mg, Semaglutide 1.0mg, Dulaglutide 4.5mg, and Semaglutide 0.5mg, Dulaglut…
    1 context sentence
    Summary · context
    Randomized clinical trials (RCTs) enrolling participants with diabetes mellitus type 2 and a follow-up of at least 12 weeks were included, for which 4 eligible GLP-1RAs Exenatide, Dulaglutide, Semaglutide, Loxenatide were compared with either each other or placebo.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 05HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In adults with type 2 diabetes, the GLP-1RA regimens (semaglutide among them) had a comparable safety profile for hypoglycemia.

    In plain wordsIn adults with type 2 diabetes, the GLP-1 drug regimens, semaglutide included, had similar low blood sugar risk.

    Peptide
    Semaglutide
    Outcome
    No significant changeHypoglycemia, GLP-1RA regimens
    Study

    n = 6,213

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    The GLP-1RA regimen has a comparable safety profile for hypoglycemia.
    1 context sentence
    Summary · context
    Randomized clinical trials (RCTs) enrolling participants with diabetes mellitus type 2 and a follow-up of at least 12 weeks were included, for which 4 eligible GLP-1RAs Exenatide, Dulaglutide, Semaglutide, Loxenatide were compared with either each other or placebo.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 06HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In adults with type 2 diabetes, long-acting GLP-1RAs other than PEX168 (semaglutide among them) had lower rates of diarrhea, nausea and vomiting than placebo.

    In plain wordsIn adults with type 2 diabetes, long-acting GLP-1 drugs as a group, semaglutide included, showed lower stomach side effect rates than placebo, except PEX168.

    Peptide
    Semaglutide
    Outcome
    DecreaseDiarrhea, nausea and vomiting, long-acting GLP-1RAs pooled
    Study

    n = 6,213

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    And with the exception of PEX168, all other long-acting GLP-1RA drugs had lower rates of diarrhea, nausea and vomiting than placebo.
    1 context sentence
    Summary · context
    Randomized clinical trials (RCTs) enrolling participants with diabetes mellitus type 2 and a follow-up of at least 12 weeks were included, for which 4 eligible GLP-1RAs Exenatide, Dulaglutide, Semaglutide, Loxenatide were compared with either each other or placebo.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    12 Oct 2026, 12:10 UTC

    Study results updated

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.